Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

- PMLiVE

Evotec and Vifor announce joint venture for kidney disease treatments

Both companies will split the clinical and commercial costs equally

Patient journey mapping: exploring the clinical and the emotional journey

By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew

- PMLiVE

Rewarding Long Service at Bedrock

Katie Penfold celebrates 5 years with the Bedrock Group

Bedrock Healthcare Communications

- PMLiVE

Restoring Equilibrium at Lucid Group

It’s National Stress Awareness Day, which is a great opportunity to take a moment to think about our wellbeing. This time of year is often busier than normal. At Lucid,...

Lucid Group Communications Limited

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

AstraZeneca AZ

AstraZeneca launches $1bn Chinese investment fund

AZ is among the top investors in the country with a strong market presence

- PMLiVE

Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

Results at six months demonstrated 75% of patients were progression-free

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

- PMLiVE

Combining hard technology with human skills

Chris Ross explores why pharma’s multichannel maturity isn’t just about hard technology – success depends on ‘human’ enablers

- PMLiVE

Aveo’s tivozanib is knocked back by FDA once again

Company says it will delay any regulatory filing until first quarter next year

Daiichi Sankyo logo

Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201

Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline

- PMLiVE

NHS leader warns politicians not to ‘weaponise’ the health service

Top exec challenges main parties to provide credible solutions to big issues

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links